{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:00:29Z","timestamp":1791561629118,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shionogi,Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antimicrobial resistance is a major threat to global health and the world economy. The economic burden of carbapenem-resistant infections has not previously been evaluated. We aimed to compare the potential economic burden and clinical outcomes between carbapenem-resistant infections and carbapenem-susceptible infections in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cohort study using electronic medical records. Patients aged 15\u00a0years or older and with the diagnosis of pneumonia, urinary tract infection, biliary infection, and sepsis were included. Multivariable regression models with random effects were used to estimate the impact of carbapenem resistance on cost, length of hospital stay, and in-hospital mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 9,517 patients, 86 (0.9%) had carbapenem-resistant (CR) infections. Compared to carbapenem-susceptible (CS) infections, the patients with the CR infections were significantly more likely to receive mechanical ventilation (37.2 vs. 21.2%, P-value\u2009=\u20090.003), antibiotics (88.4 vs. 63.0%, P-value\u2009&lt;\u20090.001), and especially carbapenem (31.4 vs. 8.3%, P-value\u2009&lt;\u20090.001), before the bacterial culture test positive. Significantly higher median costs were found for the CR infections than the CS infections in the categories of medications (3477 US dollars vs. 1609 US dollars), laboratory tests (2498 US dollars, vs. 1845 US dollars), and hospital stay (14,307 US dollars vs. 10,560 US dollars). In the multivariable regression analysis, the length of stay was 42.1% longer and the cost was 50.4% higher in the CR infections than in the CS infections. The risk of in-hospital mortality did not differ between the two groups (odds ratio 1.24, 95% CI 0.72\u20132.11), due to the small sample size. The result was robust with a similar trend in the analysis using the inverse probability treatment weighting method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared to carbapenem-susceptible infections, carbapenem-resistant infections were associated with a higher cost and a longer length of stay. Detailed cost analysis showed significant differences in the categories of medication, laboratory tests, and hospital stay. To our knowledge, this study is the first to assess the potential economic burden of carbapenem-resistant infections using a large hospital-based database.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07548-3","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T09:07:58Z","timestamp":1656493678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan"],"prefix":"10.1186","volume":"22","author":[{"given":"Shinobu","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"7548_CR1","unstructured":"World Health Organization. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. 2017. https:\/\/apps.who.int\/iris\/handle\/10665\/259462. Accessed 28 May 2022."},{"key":"7548_CR2","first-page":"34","volume":"32","author":"A Michael","year":"2019","unstructured":"Michael A, Clift C, Schulze K, Sagan A, Nahrgang S, Ouakrim DA, et al. Averting the AMR crisis: What are the avenues for policy action for countries in Europe? Eur Obs Policy Briefs. 2019;32:34.","journal-title":"Eur Obs Policy Briefs."},{"key":"7548_CR3","unstructured":"Organisation for Economic Co-operation and Development. Antimicrobial resistance\u2014OECD. https:\/\/www.oecd.org\/els\/health-systems\/antimicrobial-resistance.htm. Accessed 28 May 2022."},{"key":"7548_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jhin.2018.11.018","volume":"102","author":"YP Tabak","year":"2019","unstructured":"Tabak YP, Sung AH, Ye G, Vankeepuram L, Gupta V, McCann E. Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections. J Hosp Infect. 2019;102:37\u201344.","journal-title":"J Hosp Infect"},{"key":"7548_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/antibiotics9080514","volume":"9","author":"X Zhen","year":"2020","unstructured":"Zhen X, St\u00e5lsbyLundborg C, Sun X, Gu S, Dong H. Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: a multicenter study in China. Antibiotics. 2020;9:514.","journal-title":"Antibiotics"},{"key":"7548_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ijantimicag.2017.12.012","volume":"51","author":"CA Vargas-Alzate","year":"2018","unstructured":"Vargas-Alzate CA, Higuita-Guti\u00e9rrez LF, L\u00f3pez-L\u00f3pez L, Cienfuegos-Gallet AV, Jim\u00e9nez Quiceno JN. High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region. Int J Antimicrob Agents. 2018;51:601\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"7548_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jhin.2018.10.005","volume":"102","author":"A Tsutsui","year":"2019","unstructured":"Tsutsui A, Yahara K, Clark A, Fujimoto K, Kawakami S, Chikumi H, et al. Automated detection of outbreaks of antimicrobial-resistant bacteria in Japan. J Hosp Infect. 2019;102:226\u201333.","journal-title":"J Hosp Infect"},{"key":"7548_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1186\/s12913-018-3604-x","volume":"18","author":"A Tsutsui","year":"2018","unstructured":"Tsutsui A, Suzuki S. Japan nosocomial infections surveillance (JANIS): a model of sustainable national antimicrobial resistance surveillance based on hospital diagnostic microbiology laboratories. BMC Health Serv Res. 2018;18:799.","journal-title":"BMC Health Serv Res"},{"key":"7548_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7883\/yoken.JJID.2020.499","volume":"74","author":"T Kajihara","year":"2021","unstructured":"Kajihara T, Yahara K, Hirabayashi A, Shibayama K, Sugai M. Japan nosocomial infections surveillance (Janis): current status, international collaboration, and future directions for a comprehensive antimicrobial resistance surveillance system. Jpn J Infect Dis. 2021;74:87\u201396.","journal-title":"Jpn J Infect Dis"},{"key":"7548_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jiac.2019.10.017","volume":"26","author":"S Tsuzuki","year":"2020","unstructured":"Tsuzuki S, Matsunaga N, Yahara K, Gu Y, Hayakawa K, Hirabayashi A, et al. National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. J Infect Chemother. 2020;26:367\u201371.","journal-title":"J Infect Chemother"},{"key":"7548_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2147\/CLEP.S359072","volume":"14","author":"N Kanazawa","year":"2022","unstructured":"Kanazawa N, Tani T, Imai S, Horiguchi H, Fushimi K, Inoue N. Existing data sources for clinical epidemiology: database of the national hospital organization in Japan. Clin Epidemiol. 2022;14:689\u201398.","journal-title":"Clin Epidemiol"},{"key":"7548_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200288","volume":"31","author":"K Hayashida","year":"2021","unstructured":"Hayashida K, Murakami G, Matsuda S, Fushimi K. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31:1\u201311.","journal-title":"J Epidemiol"},{"key":"7548_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6963-7-50","volume":"7","author":"K Fushimi","year":"2007","unstructured":"Fushimi K, Hashimoto H, Imanaka Y, Kuwabara K, Horiguchi H, Ishikawa KB, et al. Functional mapping of hospitals by diagnosis-dominant case-mix analysis. BMC Health Serv Res. 2007;7:1\u20138.","journal-title":"BMC Health Serv Res"},{"key":"7548_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3414\/ME11-06-0005","volume":"50","author":"M Kimura","year":"2011","unstructured":"Kimura M, Nakayasu K, Ohshima Y, Fujita N, Nakashima N, Jozaki H, et al. SS-MIX: a ministry project to promote standardized healthcare information exchange. Methods Inf Med. 2011;50:131\u20139.","journal-title":"Methods Inf Med"},{"key":"7548_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","volume":"27","author":"H Yamana","year":"2017","unstructured":"Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476\u201382.","journal-title":"J Epidemiol"},{"key":"7548_CR16","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/jmv.25540","volume":"91","author":"S Imai","year":"2019","unstructured":"Imai S, Yamana H, Inoue N, Akazawa M, Horiguchi H, Fushimi K, et al. Validity of administrative database detection of previously resolved hepatitis B virus in Japan. J Med Virol. 2019;91:1944\u20138.","journal-title":"J Med Virol"},{"key":"7548_CR17","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"7548_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.21037\/atm.2018.08.13","volume":"6","author":"H-Q Gu","year":"2018","unstructured":"Gu H-Q, Li D-J, Liu C, Rao Z-Z. %ggBaseline: a SAS macro for analyzing and reporting baseline characteristics automatically in medical research. Ann Transl Med. 2018;6:326\u2013326.","journal-title":"Ann Transl Med."},{"key":"7548_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1472-6963-12-122","volume":"12","author":"E Morales","year":"2012","unstructured":"Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122.","journal-title":"BMC Health Serv Res"},{"key":"7548_CR20","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661\u201379.","journal-title":"Stat Med"},{"key":"7548_CR21","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1177\/0962280215584401","volume":"26","author":"PC Austin","year":"2017","unstructured":"Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res. 2017;26:1654\u201370.","journal-title":"Stat Methods Med Res"},{"key":"7548_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399\u2013424.","journal-title":"Multivariate Behav Res."},{"key":"7548_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113:390\u2013400.","journal-title":"J Am Stat Assoc"},{"key":"7548_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy265","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol. 2019;188:250\u20137.","journal-title":"Am J Epidemiol"},{"key":"7548_CR25","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.jval.2019.06.010","volume":"22","author":"T Mlcoch","year":"2019","unstructured":"Mlcoch T, Hrnciarova T, Tuzil J, Zadak J, Marian M, Dolezal T. Propensity score weighting using overlap weights: a new method applied to regorafenib clinical data and a cost-effectiveness analysis. Value Heal. 2019;22:1370\u20137.","journal-title":"Value Heal."},{"key":"7548_CR26","unstructured":"R Core Team. R: A language and environment for statistical computing. 2022. https:\/\/www.r-project.org\/. Accessed 4 Jun 2022."},{"key":"7548_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jhin.2020.03.009","volume":"105","author":"AJ Rodriguez-Acevedo","year":"2020","unstructured":"Rodriguez-Acevedo AJ, Lee XJ, Elliott TM, Gordon LG. Hospitalization costs for patients colonized with carbapenemase-producing Enterobacterales during an Australian outbreak. J Hosp Infect. 2020;105:146\u201353.","journal-title":"J Hosp Infect"},{"key":"7548_CR28","first-page":"668","volume":"72","author":"E Righi","year":"2017","unstructured":"Righi E, Peri AM, Harris PNA, Wailan AM, Liborio M, Lane SW, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:668\u201377.","journal-title":"J Antimicrob Chemother"},{"key":"7548_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13756-020-0682-4","volume":"9","author":"MC Persoon","year":"2020","unstructured":"Persoon MC, VoorIn\u2019T Holt AF, Wielders CCH, Gommers D, Vos MC, Severin JA. Mortality associated with carbapenem-susceptible and Verona Integron-encoded Metallo-\u03b2-lactamase-positive Pseudomonas aeruginosa bacteremia. Antimicrob Resist Infect Control. 2020;9:107.","journal-title":"Antimicrob Resist Infect Control"},{"key":"7548_CR30","unstructured":"Ministry of Health L and W. Results of the \u201cSurvey on New Multidrug-Resistant Bacteria in Japan\u201d [Japanese]. 2011. https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/kekkaku-kansenshou19\/cyousa_kekka_110121.html. Accessed 4 Jun 2022."},{"key":"7548_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jgar.2022.04.004","volume":"29","author":"K Oka","year":"2022","unstructured":"Oka K, Matsumoto A, Tetsuka N, Morioka H, Iguchi M, Ishiguro N, et al. Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan. J Glob Antimicrob Resist. 2022;29:247\u201352.","journal-title":"J Glob Antimicrob Resist."},{"key":"7548_CR32","first-page":"1511","volume":"63","author":"X Wang","year":"2019","unstructured":"Wang X, Wang Q, Cao B, Sun S, Zhang Y, Gu B, et al. Retrospective observational study from a chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant enterobacteriaceae bacteremia. Antimicrob Agents Chemother. 2019;63:1511\u201329.","journal-title":"Antimicrob Agents Chemother"},{"key":"7548_CR33","first-page":"1189","volume":"10","author":"S Suzuki","year":"2021","unstructured":"Suzuki S. A view on 20 years of antimicrobial resistance in Japan by two national surveillance systems: the National Epidemiological Surveillance of Infectious Diseases and Japan Nosocomial Infections Surveillance. Antibiot (Basel, Switzerland). 2021;10:1189.","journal-title":"Antibiot (Basel, Switzerland)."},{"key":"7548_CR34","unstructured":"National Institute of Infectious Diseases. IASR Vol.40, No.2 (No.468), February 2019 Special Issue Carbapenem-Resistant Enterobacteriaceae (CRE) Infections. 2019. https:\/\/www.niid.go.jp\/niid\/ja\/iasr-vol40\/8612-idx468.html. Accessed 28 May 2022."},{"key":"7548_CR35","unstructured":"Carbapenem-resistant Enterobacteriaceae from the Japanese Ministry of Health, Labour and Welfare Nosocomial Infection Control Surveillance (JANIS) data [Japanese]. 2019. https:\/\/www.niid.go.jp\/niid\/ja\/typhi-m\/iasr-reference\/2439-related-articles\/related-articles-468\/8617-468r03.html. Accessed 8 Jun 2022."},{"key":"7548_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.12998\/wjcc.v2.i12.787","volume":"2","author":"M-F Lin","year":"2014","unstructured":"Lin M-F, Lan C-Y. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases WJCC. 2014;2:787.","journal-title":"World J Clin Cases WJCC."},{"key":"7548_CR37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","volume":"20","author":"TP Lodise","year":"2022","unstructured":"Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022;20:707\u201319.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"7548_CR38","unstructured":"OECD. Health at a Glance 2021\u2014length of hospital stay. 2021. https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/health-at-a-glance-2021_ae3016b9-en. Accessed 28 May 2022."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07548-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T09:09:45Z","timestamp":1656493785000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07548-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7548"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07548-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study conforms to the provisions of the Declaration of Helsinki and was approved by the Institutional Review Board of the NHO Headquarters [R2-0827006]. Due to the retrospective and noninvasive nature of the study with anonymized data, the need for informed consent was waived by the approval of the Institutional Review Board of the NHO Headquarters, according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects, established by the Ministry of Health, Labour and Welfare, Ministry of Education, Culture, Sports, Science and Technology, and Ministry of Economy, Trade and Industry, in Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"S.I., N.I., and H.N. are employees of the National Hospital Organization, which received joint research fees from Shionogi & Co., Ltd. The authors report no other competing interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"581"}}